[{"id":"b727510f-e4dd-45d1-a75b-a7fd6215444a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03598244","created_at":"2021-01-18T17:41:26.385Z","updated_at":"2025-02-25T14:15:11.442Z","phase":"Phase 1","brief_title":"Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors","source_id_and_acronym":"NCT03598244","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" MET amplification","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/27/2018","start_date":" 11/27/2018","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-18"},{"id":"c2c0bdf4-79cd-4e7d-b1f6-9bf7bf2f7d00","acronym":"SAVOIR","url":"https://clinicaltrials.gov/study/NCT03091192","created_at":"2021-01-17T17:49:25.734Z","updated_at":"2025-02-25T15:10:33.304Z","phase":"Phase 3","brief_title":"Savolitinib vs. Sunitinib in MET-driven PRCC.","source_id_and_acronym":"NCT03091192 - SAVOIR","lead_sponsor":"AstraZeneca","biomarkers":" VHL","pipe":" | ","alterations":" VHL mutation","tags":["VHL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Orpathys (savolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/25/2017","start_date":" 07/25/2017","primary_txt":" Primary completion: 08/18/2019","primary_completion_date":" 08/18/2019","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-13"},{"id":"242a6457-aef1-4b8b-890a-953bd32e515a","acronym":"SAVANNAH","url":"https://clinicaltrials.gov/study/NCT03778229","created_at":"2021-01-18T18:41:19.683Z","updated_at":"2025-02-25T15:34:16.664Z","phase":"Phase 2","brief_title":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","source_id_and_acronym":"NCT03778229 - SAVANNAH","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR amplification • MET overexpression","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR amplification • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Orpathys (savolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 367","initiation":"Initiation: 01/09/2019","start_date":" 01/09/2019","primary_txt":" Primary completion: 08/23/2024","primary_completion_date":" 08/23/2024","study_txt":" Completion: 05/28/2025","study_completion_date":" 05/28/2025","last_update_posted":"2025-02-10"},{"id":"ece1e947-6ee1-43ee-ad69-399f7ff3106a","acronym":"CoC","url":"https://clinicaltrials.gov/study/NCT04606771","created_at":"2021-01-19T20:31:36.655Z","updated_at":"2025-02-25T17:00:42.361Z","phase":"Phase 2","brief_title":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC","source_id_and_acronym":"NCT04606771 - CoC","lead_sponsor":"AstraZeneca","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Orpathys (savolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/28/2020","start_date":" 09/28/2020","primary_txt":" Primary completion: 12/21/2022","primary_completion_date":" 12/21/2022","study_txt":" Completion: 03/28/2025","study_completion_date":" 03/28/2025","last_update_posted":"2025-02-03"},{"id":"12b5c747-ed51-4685-a2bb-fc3b4832f8ea","acronym":"CALYPSO","url":"https://clinicaltrials.gov/study/NCT02819596","created_at":"2021-01-18T13:49:36.169Z","updated_at":"2025-02-25T15:07:06.837Z","phase":"Phase 2","brief_title":"MEDI4736 Combinations in Metastatic Renal Cell Carcinoma","source_id_and_acronym":"NCT02819596 - CALYPSO","lead_sponsor":"Queen Mary University of London","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Orpathys (savolitinib)"],"overall_status":"Completed","enrollment":" Enrollment 69","initiation":"Initiation: 05/03/2016","start_date":" 05/03/2016","primary_txt":" Primary completion: 07/17/2024","primary_completion_date":" 07/17/2024","study_txt":" Completion: 07/17/2024","study_completion_date":" 07/17/2024","last_update_posted":"2024-11-04"},{"id":"eb48e074-c9c1-4740-b335-db17f9ac4451","acronym":"PAPMET","url":"https://clinicaltrials.gov/study/NCT02761057","created_at":"2024-02-04T01:56:06.891Z","updated_at":"2024-07-02T16:34:26.084Z","phase":"Phase 2","brief_title":"Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed","source_id_and_acronym":"NCT02761057 - PAPMET","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" MET mutation • MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET mutation • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • sunitinib • Cabometyx (cabozantinib tablet) • Orpathys (savolitinib) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 07/25/2016","start_date":" 07/25/2016","primary_txt":" Primary completion: 10/02/2023","primary_completion_date":" 10/02/2023","study_txt":" Completion: 12/12/2024","study_completion_date":" 12/12/2024","last_update_posted":"2024-06-14"},{"id":"13166d68-2e61-4c72-92f1-fac024df7835","acronym":"SAFFRON","url":"https://clinicaltrials.gov/study/NCT05261399","created_at":"2022-03-02T17:52:38.442Z","updated_at":"2024-07-02T16:34:59.035Z","phase":"Phase 3","brief_title":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment","source_id_and_acronym":"NCT05261399 - SAFFRON","lead_sponsor":"AstraZeneca","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR overexpression • MET overexpression • MET mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR overexpression • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 324","initiation":"Initiation: 08/03/2022","start_date":" 08/03/2022","primary_txt":" Primary completion: 06/26/2025","primary_completion_date":" 06/26/2025","study_txt":" Completion: 12/17/2026","study_completion_date":" 12/17/2026","last_update_posted":"2024-06-04"},{"id":"149137c3-0ac6-4627-8ec7-485b316d9bc0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04322578","created_at":"2021-01-27T19:00:13.739Z","updated_at":"2024-07-02T16:34:58.985Z","phase":"Phase 2","brief_title":"Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC","source_id_and_acronym":"NCT04322578","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" MET","pipe":"","alterations":" ","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Xalkori (crizotinib) • carboplatin • pemetrexed • Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/24/2020","start_date":" 03/24/2020","primary_txt":" Primary completion: 03/24/2025","primary_completion_date":" 03/24/2025","study_txt":" Completion: 03/24/2026","study_completion_date":" 03/24/2026","last_update_posted":"2024-06-04"},{"id":"59529bbb-f615-4981-937f-6ac29b7ec1c3","acronym":"PIKACHU","url":"https://clinicaltrials.gov/study/NCT04322890","created_at":"2021-01-18T20:56:40.742Z","updated_at":"2024-07-02T16:34:59.292Z","phase":"Phase 2","brief_title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","source_id_and_acronym":"NCT04322890 - PIKACHU","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2027","study_completion_date":" 12/24/2027","last_update_posted":"2024-06-04"},{"id":"059c44d0-f5a3-4e0a-b39e-6b8103e251ad","acronym":"PIONeeR","url":"https://clinicaltrials.gov/study/NCT03833440","created_at":"2021-01-18T18:55:39.473Z","updated_at":"2024-07-02T16:35:06.100Z","phase":"Phase 2","brief_title":"Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance","source_id_and_acronym":"NCT03833440 - PIONeeR","lead_sponsor":"Assistance Publique Hopitaux De Marseille","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • docetaxel • Orpathys (savolitinib) • ceralasertib (AZD6738) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 10/08/2019","start_date":" 10/08/2019","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-03"},{"id":"ba256708-bd68-4aa8-a289-341634b3901f","acronym":"SOUND","url":"https://clinicaltrials.gov/study/NCT05374603","created_at":"2022-05-16T13:53:43.301Z","updated_at":"2024-07-02T16:35:16.700Z","phase":"Phase 2","brief_title":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC","source_id_and_acronym":"NCT05374603 - SOUND","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • MET","pipe":" | ","alterations":" MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET mutation","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Orpathys (savolitinib)"],"overall_status":"Suspended","enrollment":" Enrollment 60","initiation":"Initiation: 11/23/2022","start_date":" 11/23/2022","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-01"},{"id":"f2a04229-a963-4571-967a-2d4ee1ac84df","acronym":"FLOWERS","url":"https://clinicaltrials.gov/study/NCT05163249","created_at":"2021-12-20T15:53:31.602Z","updated_at":"2024-07-02T16:35:19.919Z","phase":"Phase 2","brief_title":"Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC","source_id_and_acronym":"NCT05163249 - FLOWERS","lead_sponsor":"Guangdong Association of Clinical Trials","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • MET amplification • MET overexpression • MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • MET overexpression • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Orpathys (savolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 05/31/2022","start_date":" 05/31/2022","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-02-09"},{"id":"2d001bd0-721f-4093-a13e-a279286606b0","acronym":"FirstMET","url":"https://clinicaltrials.gov/study/NCT05777278","created_at":"2023-03-21T14:02:59.639Z","updated_at":"2024-07-02T16:35:34.134Z","phase":"Phase 1/2","brief_title":"Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression","source_id_and_acronym":"NCT05777278 - FirstMET","lead_sponsor":"The First Affiliated Hospital of Guangzhou Medical University","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" MET overexpression","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":" Primary completion: 08/31/2027","primary_completion_date":" 08/31/2027","study_txt":" Completion: 08/31/2027","study_completion_date":" 08/31/2027","last_update_posted":"2023-10-10"},{"id":"34d5b5f4-1e3a-4200-8350-19e639ccf1ab","acronym":"SANOVO","url":"https://clinicaltrials.gov/study/NCT05009836","created_at":"2021-08-18T15:53:38.104Z","updated_at":"2024-07-02T16:35:51.870Z","phase":"Phase 3","brief_title":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC","source_id_and_acronym":"NCT05009836 - SANOVO","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET overexpression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 09/06/2021","start_date":" 09/06/2021","primary_txt":" Primary completion: 11/15/2024","primary_completion_date":" 11/15/2024","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2023-03-30"},{"id":"4badf5d7-a3d4-4d55-9d0d-559af1b94b4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04923932","created_at":"2021-06-11T18:56:20.278Z","updated_at":"2024-07-02T16:35:51.916Z","phase":"Phase 2","brief_title":"Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients","source_id_and_acronym":"NCT04923932","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" MET","pipe":" | ","alterations":" MET amplification","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 07/27/2021","start_date":" 07/27/2021","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-03-30"},{"id":"c84e06b6-d517-4cfc-ae1f-9c0ba25c0036","acronym":"SACHI","url":"https://clinicaltrials.gov/study/NCT05015608","created_at":"2021-08-20T14:53:13.438Z","updated_at":"2024-07-02T16:35:51.944Z","phase":"Phase 3","brief_title":"Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification","source_id_and_acronym":"NCT05015608 - SACHI","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • MET amplification","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 11/22/2021","start_date":" 11/22/2021","primary_txt":" Primary completion: 09/15/2024","primary_completion_date":" 09/15/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2023-03-30"},{"id":"3ec3dc6a-826c-4937-a5cc-c4ecb773e8b7","acronym":"VIKTORY-2","url":"https://clinicaltrials.gov/study/NCT05620628","created_at":"2022-11-17T14:57:07.211Z","updated_at":"2024-07-02T16:35:57.801Z","phase":"Phase 2","brief_title":"Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)","source_id_and_acronym":"NCT05620628 - VIKTORY-2","lead_sponsor":"Jeeyun Lee","biomarkers":" MET","pipe":" | ","alterations":" MET amplification","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 01/05/2023","start_date":" 01/05/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-01-11"},{"id":"cbc53d69-2883-4ae3-87e8-9b8785948809","acronym":"","url":"https://clinicaltrials.gov/study/NCT02447406","created_at":"2021-01-18T11:43:45.734Z","updated_at":"2024-07-02T16:36:08.725Z","phase":"Phase 2","brief_title":"Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment","source_id_and_acronym":"NCT02447406","lead_sponsor":"Samsung Medical Center","biomarkers":" MET","pipe":" | ","alterations":" MET amplification","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Orpathys (savolitinib)"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 04/30/2015","start_date":" 04/30/2015","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 09/20/2020","study_completion_date":" 09/20/2020","last_update_posted":"2022-06-15"},{"id":"e7056cd1-17db-4e5d-86ca-e2458c39691b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02449551","created_at":"2021-01-18T11:44:38.574Z","updated_at":"2024-07-02T16:36:08.709Z","phase":"Phase 2","brief_title":"Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment","source_id_and_acronym":"NCT02449551","lead_sponsor":"Samsung Medical Center","biomarkers":" MET","pipe":" | ","alterations":" MET amplification","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orpathys (savolitinib)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 02/10/2016","start_date":" 02/10/2016","primary_txt":" Primary completion: 12/30/2020","primary_completion_date":" 12/30/2020","study_txt":" Completion: 08/27/2021","study_completion_date":" 08/27/2021","last_update_posted":"2022-06-15"},{"id":"8e2a9584-ca14-4fbe-9cd2-79c594324926","acronym":"","url":"https://clinicaltrials.gov/study/NCT02897479","created_at":"2021-01-17T17:17:30.933Z","updated_at":"2024-07-02T16:36:20.081Z","phase":"Phase 2","brief_title":"A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02897479","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" MET","pipe":" | ","alterations":" MET exon 14 mutation • MET mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orpathys (savolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 12/30/2021","primary_completion_date":" 12/30/2021","study_txt":" Completion: 12/30/2021","study_completion_date":" 12/30/2021","last_update_posted":"2021-11-30"},{"id":"48a948a4-7790-489f-81c0-aebfce737e09","acronym":"","url":"https://clinicaltrials.gov/study/NCT04923945","created_at":"2021-06-11T18:56:20.507Z","updated_at":"2024-07-02T16:36:24.953Z","phase":"Phase 3","brief_title":"Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients","source_id_and_acronym":"NCT04923945","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" MET","pipe":" | ","alterations":" MET exon 14 mutation • MET mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 163","initiation":"Initiation: 08/19/2021","start_date":" 08/19/2021","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2021-09-02"},{"id":"ffd7f665-f8bb-4379-a0da-85ba42059c2b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04187456","created_at":"2021-01-18T20:24:44.547Z","updated_at":"2024-07-02T16:36:26.138Z","phase":"Phase 1","brief_title":"A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body","source_id_and_acronym":"NCT04187456","lead_sponsor":"AstraZeneca","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orpathys (savolitinib) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 12/27/2019","start_date":" 12/27/2019","primary_txt":" Primary completion: 03/06/2020","primary_completion_date":" 03/06/2020","study_txt":" Completion: 03/06/2020","study_completion_date":" 03/06/2020","last_update_posted":"2021-08-19"},{"id":"19836859-5906-4b14-9203-a5e70e7ff26f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02127710","created_at":"2021-01-18T09:51:46.376Z","updated_at":"2024-07-02T16:36:31.582Z","phase":"Phase 2","brief_title":"A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)","source_id_and_acronym":"NCT02127710","lead_sponsor":"AstraZeneca","biomarkers":" MET • IL2","pipe":"","alterations":" ","tags":["MET • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orpathys (savolitinib)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 04/30/2014","start_date":" 04/30/2014","primary_txt":" Primary completion: 04/14/2016","primary_completion_date":" 04/14/2016","study_txt":" Completion: 04/20/2020","study_completion_date":" 04/20/2020","last_update_posted":"2021-04-19"},{"id":"8ef02209-9fbb-4f43-9d72-74aec4dc298f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04118842","created_at":"2021-01-18T20:07:50.696Z","updated_at":"2024-07-02T16:36:46.689Z","phase":"Phase 1","brief_title":"A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin","source_id_and_acronym":"NCT04118842","lead_sponsor":"AstraZeneca","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orpathys (savolitinib) • rifampicin"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 10/17/2019","start_date":" 10/17/2019","primary_txt":" Primary completion: 02/26/2020","primary_completion_date":" 02/26/2020","study_txt":" Completion: 02/26/2020","study_completion_date":" 02/26/2020","last_update_posted":"2020-04-03"}]